Cardiovascular disease [dsyn]
Aromatase inhibitor [phsu]
Cardiovascular disease [dsyn]
Death [orgf]
Old [tmco]
Patients [podg]
Breast Cancer [neop]
Limited [ftcn]
Information [idcn]
Exist [cnce]
Long-Term Effect [phpr]
Aromatase inhibitor [phsu]
cardiovascular cancer [neop]
disease risk [fndg]
Breast [bpoc]
Survivors [podg]
Point [qnco]
Population Based Study [resa]
Able [orga]
cardiovascular risk factor [dsyn]
Disease [dsyn]
CARDIOVASCULAR MEDICATIONS [phsu]
Objective [inpr]
Long-term [tmco]
influential [idcn]
adjuvant therapy [topp]
Endocrine [bdsy]
Cardiovascular disease [dsyn]
Cohort [popg]
postmenopausal [tmco]
Breast Cancer [neop]
Survivors [podg]
Analysis [lbpr]
account [idcn]
Major [qlco]
cardiovascular risk factor [dsyn]
Disease [dsyn]
medication use [fndg]
Chemotherapy [topp]
radiotherapy [inpr]
Design [acty]
setting [ftcn]
participants [popg]
retrospective [resa]
Cohort [popg]
postmenopausal [tmco]
Women [popg]
Breast Cancer [neop]
Diagnosed [fndg]
Maximum [qnco]
Person [popg]
Evaluated [ftcn]
Using [ftcn]
Records [inpr]
Managed Care Organization [hcro, mnob]
Hospitals, Community [hcro, mnob]
California [geoa]
postmenopausal [tmco]
Women [popg]
Hormone Receptor [aapp, rcpt]
Breast Cancer [neop]
Prior [tmco]
Cardiovascular disease [dsyn]
included [ftcn]
Cardiovascular disease [dsyn]
Incidence [qnco]
Compared [acty]
Endocrine therapy [topp]
Categories [inpr]
Information [idcn]
Demographics [idcn]
Comorbidity [idcn]
Medication [phsu]
Cardiovascular disease [dsyn]
Risk [qlco]
Electronic Health Records [inpr]
Cox Proportional Hazards Models [inpr, qnco]
Using [ftcn]
Time [tmco]
dependent drug [fndg]
Endocrine [bdsy]
variables [qlco]
Scores, Propensity [qnco]
Conduct [inbe]
Data Analysis [ocac]
Conduct [inbe]
exposures [inpo]
Women [popg]
Grouped [spco]
Endocrine therapy [topp]
Status [qlco]
Tamoxifen Citrate [orch, phsu]
Only [qnco]
Aromatase inhibitor [phsu]
Only [qnco]
Main [qlco]
Outcome [ftcn]
Measure [qnco]
Person [popg]
Rate [acty]
Cardiovascular disease [dsyn]
therapy [ftcn]
Group [idcn]
Result [ftcn]
Person [popg]
Women [popg]
Mean [qnco]
SD [fndg]
Age [orga]
Follow-up [fndg]
Observed [ftcn]
cardiovascular events [fndg]
Disease [dsyn]
Analysis [lbpr]
Reported [inpr]
Hazard Ratio [qnco]
Aromatase inhibitor [phsu]
Only [qnco]
Users [humn]
Similar [qlco]
Risk [qlco]
cardiac ischaemia [dsyn]
Myocardial Infarction [dsyn]
Angina [sosy]
Adjusted [ftcn]
Stroke [dsyn]
Adjusted [ftcn]
Tamoxifen [orch, phsu]
Only [qnco]
Users [humn]
Reference [idcn]
Found [qnco]
Increased [qnco]
Risk [qlco]
Cardiovascular disease [dsyn]
dysrhythmia [patf]
dysfunction [ftcn]
Pericarditis [dsyn]
Adjusted [ftcn]
Women [popg]
Only [qnco]
Tamoxifen [orch, phsu]
Tamoxifen [orch, phsu]
Reference [idcn]
Well [qlco]
Users [humn]
Conclusions [idcn]
Relevance [qlco]
Risk [qlco]
Most [qnco]
Serious [qlco]
cardiovascular events [fndg]
cardiac ischaemia [dsyn]
Stroke [dsyn]
Not [ftcn]
Elevated [qlco]
Aromatase inhibitor [phsu]
Only [qnco]
Users [humn]
Compared [acty]
Tamoxifen [orch, phsu]
Users [humn]
Finding [sosy]
cardiovascular events [fndg]
Disease [dsyn]
Combined [qlco]
Aromatase inhibitor [phsu]
Users [humn]
Further [spco]
Study [mnob]
